Human Visfatin EIA


RayBio® Human/Mouse/Rat Visfatin EIA Kit optimized for serum and cell culture medium. Competition-based ELISA on a 96-well strip plate.


Obesity, which is characterized by excessive accumulation of adipose tissue in the body, has become one of the greatest public health challenges. Obesity is not only associated with health problems linked to increased weight-dependent pressure overload on lung, joints and bones, but also a important risk factor for life-threatening diseases such as cardiovascular diseases, type 2 diabetes and certain cancers.

Visfatin, an adipokine that is highly enriched in the visceral fat, has increased expression level in plasma during the development of obesity, implying its important role in obesity.

Visfatin (also known as PBEF and Nampt), a 52 kDa cytoplasmic protein composed of 473-amino acids, is expressed primarily in bone marrow, muscle and liver tissue but can also be detected in placenta, lung, kidney and heart tissue.

In addition to its role in obesity, visfatin also has other biological functions. Visfatin is a nicotinamide phosphoribosyltransferase (Nampt) enzyme that catalyzes first step in the biosynthesis of NAD from nicotinamide. Visfatin has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis.

Product Features

  • Strip plates and additional reagents allow for use in multiple experiments
  • Quantitative protein detection
  • Establishes normal range
  • The best products for confirmation of antibody array data


The capture antibody provided in this kit recognizes human, mouse and rat Visfatin.

Target Protein Information

Nicotinamide phosphoribosyltransferase (NAmPRTase) (Nampt) (EC (Pre-B-cell colony-enhancing factor 1) (Pre-B cell-enhancing factor) (Visfatin)
Accession Number
Gene Names
Gene ID

Application Notes

Kit Components
  • Pre-Coated 96-well Strip Microplate
  • Wash Buffer
  • Standard Peptide
  • Assay Diluent(s)
  • Biotinylated Peptide
  • HRP-Streptavidin
  • TMB One-Step Substrate
  • Stop Solution
  • Assay Diagram
  • Positive Control Sample
  • Capture Antibody
  • User Manual
Other Materials Required
  • Distilled or deionized water
  • Precision pipettes to deliver 2 µl to 1 ml volumes
  • Adjustable 1-25 ml pipettes for reagent preparation
  • 100 ml and 1 liter graduated cylinders
  • Tubes to prepare standard and sample dilutions
  • Orbital shaker
  • Aluminum foil
  • Saran Wrap
  • Absorbent paper
  • Microplate reader capable of measuring absorbance at 450nm
  • SigmaPlot software (or other software that can perform four-parameter logistic regression models)
Protocol Outline
  • Prepare all reagents, samples and standards as instructed.
  • Add 100 µl detection antibody to each well.
  • Incubate 1.5 h at RT or O/N at 4°C.
  • Add 100 µl standard or sample to each well.
  • Incubate 2.5 h at RT.
  • Add 100 µl prepared streptavidin solution.
  • Incubate 45 min at RT.
  • Add 100 µl TMB One-Step Substrate Reagent to each well.
  • Incubate 30 min at RT.
  • Add 50 µl Stop Solution to each well.
  • Read plate at 450 nm immediately.
  • Storage/Stability

    Standard, Biotinylated Visfatin peptide, and Positive Control should be stored at -20°C after arrival. Avoid multiple freeze-thaws. The remaining kit components may be stored at 4°C. Opened Microplate Wells and antibody (Item N) may be stored for up to 1 month at 2° to 8°C. Return unused wells to the pouch containing desiccant pack and reseal along entire edge.

    Antigen Information

    Gene Symbol:
    • NAMPT

    Product Specifications

    1, 2, or 5 x 96-Well Strip Microplate Kit

    Array/ELISA Format

    Species Detected:
    • Human
    • Mouse
    • Rat
    Solid Support:
    96-well Microplate
    Design Principle:
    • Competition-based
    Method of Detection:
    Compatible Sample Types:
    • Serum

    1. Elgarhy L. Abdelnabi N., Abdullatif A., et al. Circulating endothelial cells and serum visfatin are indicators of cardiovascular disease risk in psoriasis patients. Dermatologica Sinica, Volume 34, Issue 1, March 2016, Pages 20-25,
      Species: Human
      Sample Type: Serum

    2. Pisani D., Dumortier O., Beranger G., et al. Visfatin expression analysis in association with recruitment and activation of human and rodent brown and brite adipocytes. Adipocyte. 2016 Apr-Jun; 5(2): 186-195. doi: 10.1080/21623945.2015.1122854

    3. Keshk W., Noeman S. Impact of Chicory-Supplemented Diet on HMG-CoA Reductase, Acetyl-CoA Carboxylase, Visfatin and Anti-Oxidant Status in Triton WR-1339-Induced Hyperlipidemia. Journal of Food Biochemistry Vol 39 Iss 2, April 2015, 164-172. DOI: 10.1111/jfbc.12115
      Species: Rat
      Sample Type: Serum

    4. Luizon M., Belo V., Palei A., et al. Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy. Hypertens Res. 2015 May;38(5):361-6. doi: 10.1038/hr.2015.15.
      Species: Human
      Sample Type: Plasma

    5. Wu Y., Chen L., Wei B., et al. Effect of non-surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus. J Periodontol. 2015 Jun;86(6):795-800. doi: 10.1902/jop.2015.140476
      Species: Human
      Sample Type: Gingival Crevicular Fluid

    6. Souza-Smith F., Siggins R., Molina P. Mesenteric Lymphatic-Perilymphatic Adipose Crosstalk: Role in Alcohol-Induced Perilymphatic Adipose Tissue Inflammation. Alcohol Clin Exp Res. 2015 Aug;39(8):1380-7. doi: 10.1111/acer.12796.
      Species: Rat
      Sample Type: Plasma

    7. Rodrigues K., Pietrani N., Bosco A., et al. Visfatin levels are decreased in advanced stages of diabetic nephropathy. Ren Fail. 2015;37(9):1529-30. doi: 10.3109/0886022X.2015.1074520.
      Species: Human
      Sample Type: Serum

    8. Shaker O., Abdelhafez-M., Fayez S., and Alsherif Y. Phosphatidylinositol 3-Kinase and Insulin Receptor Substrate-1 Gene Polymorphism / Adipocytokines Interaction in Pathogenesis of Insulin Resistance among Egyptian Patients: A Pilot Study. International Journal of Research Studies in Biosciences (IJRSB) Volume 3, Issue 9, September 2015, PP 81-93 ISSN 2349-0357 (Print) & ISSN 2349-0365 (Online)
      Species: Human
      Sample Type: Serum

    9. Gumus U., et al. Plasma visfatin levels in adolescents with polycystic ovary syndrome: A prospective case-control study. Journal of Pediatric and Adolescent Gynecology. Sept 2014, epub ahead of print. DOI: 10.1016/j.jpag.2014.08.007
      Species: Human
      Sample Type: Plasma

    10. Hassan A., et al. Assessment of Visfatin and Risk Factors in Relation with Diabetic Mellitus Type II. Life Science Journal 2014;11(9s)
      Species: Human
      Sample Type: Serum

    11. Guzel S., et al. Visfatin, Leptin, and TNF-α: Interrelated Adipokines in Insulin-Resistant Clinical and Subclinical Hypothyroidism. Endocrine Research. Aug2013, Vol. 38 Issue 3, p184-194. DOI:10.3109/07435800.2012.760588
      Species: Human
      Sample Type: Serum

    12. Mabrouk R., et al. Serum Visfatin, Resistin and IL-18 in A Group of Egyptian Obese Diabetic and Non Diabetic Individuals. THE EGYPTIAN JOURNAL OF IMMUNOLOGY Vol. 20 (1), 2013
      Species: Human
      Sample Type: Serum

    13. Yanni D., et al. The role of leptin, soluble leptin receptor, adiponectin and visfatin in insulin sensitivity in preterm born children in prepubertal ages. Cytokine 64 (2013) 448-453.
      Species: Human
      Sample Type: Serum

    14. El-Shafey E., El-Naggar G., Al-Bedewy M., El-Sorogy H. Is There A Relationship Between Visfatin Level and Type 2 Diabetes Mellitus In Obese And Non Obese Patients? J Diabetes Metab 2012, S:11:001
      Species: Human
      Sample Type: Serum

    15. Guducu N., Isci H., Gormus U., et al. Serum visfatin levels in women with polycystic ovary syndrome. Gynecol Endocrinol. 2012 Aug;28(8):619-23. doi: 10.3109/09513590.2011.650749
      Species: Human
      Sample Type: Plasma

    16. Karakan S., Sezer S., Ozdemir A., Haberal M. The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients. Ren Fail. 2012;34(6):732-7. doi: 10.3109/0886022X.2012.676493.
      Species: Human
      Sample Type: Serum

    Write a review

    No posts found

    U.S. International


    This product is furnished for LABORATORY RESEARCH USE ONLY.
    Not for diagnostic or therapeutic use.

    Cart content Cart content